ICCC - ImmuCell Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Total Revenue
13,723
13,723
10,986
10,431
9,544
Cost of Revenue
6,983
6,983
5,792
5,210
4,123
Gross Profit
6,740
6,740
5,194
5,221
5,421
Operating Expenses
Research Development
3,688
3,688
3,517
2,047
1,244
Selling General and Administrative
4,006
4,006
3,824
3,418
3,286
Total Operating Expenses
7,694
7,694
7,340
5,464
4,530
Operating Income or Loss
-954
-954
-2,147
-242.845
890.204
Interest Expense
-
-
427.782
218.571
161.697
Total Other Income/Expenses Net
-314
-314
700
6.027
-24.847
Income Before Tax
-1,268
-1,268
-1,860
-438.48
758.322
Income Tax Expense
28
28
461.62
-270.333
249.874
Income from Continuing Operations
-1,296
-1,296
-2,322
-168.147
508.448
Net Income
-1,296
-1,296
-2,322
-168.147
508.448
Net Income available to common shareholders
-1,296
-1,296
-2,322
-168.147
508.448
Basic EPS
-
-
-0.42
-0.03
0.12
Diluted EPS
-
-
-0.42
-0.03
0.12
Basic Average Shares
-
-
5,486
4,949
4,226
Diluted Average Shares
-
-
5,486
4,949
4,336
EBITDA
-
-954
88.442
684.526
1,722